Risk of haematological malignancy in PsA Nordic cohorts *40 events, IR 67/100 000 person-years *NO difference between PsA bionaive and TNFi treated BUT *⬆️ in PsA vs. matched controls *no difference between myeloid and lymphoid malignancies. OP0257 #EULAR2022 @RheumNow https://t.co/oIojobgDP3